Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc, a leading biopharmaceutical company headquartered in Ireland (IE), focuses on developing innovative therapies for patients with central nervous system disorders. Founded in 1990, Avadel has established a strong presence in the global pharmaceutical industry, particularly in the United States and Europe. The company is renowned for its unique drug delivery technologies, which enhance the efficacy and safety of its core products, including treatments for narcolepsy and other sleep disorders. Avadel's commitment to addressing unmet medical needs has positioned it as a key player in the market, with notable achievements in regulatory approvals and partnerships that bolster its growth trajectory. With a focus on patient-centric solutions, Avadel Pharmaceuticals continues to advance its mission of improving lives through innovative healthcare solutions.
DitchCarbon Score
How does Avadel Pharmaceuticals plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Avadel Pharmaceuticals plc's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Avadel Pharmaceuticals plc's reported carbon emissions
Avadel Pharmaceuticals plc, headquartered in Ireland (IE), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Avadel Pharmaceuticals may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the pharmaceutical industry increasingly prioritises environmental responsibility, it will be essential for Avadel to consider developing and communicating its climate strategies to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Avadel Pharmaceuticals plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
